Deutsche Bank AG Invests $3.56 Million in Iovance Biotherapeutics, Inc. $IOVA

Key Points

• Deutsche Bank acquired 854,973 shares of Iovance Biotherapeutics during the second quarter, valued at approximately $3.56 million and representing about 0.19% of the company.
• Institutional ownership remains high at 77.03%, with several major investors—including State Street, Vanguard, UBS and HRT Financial—increasing their positions.
• Analyst sentiment is mixed but improving: the consensus rating is “Hold” with an $8.89 price target, while Iovance reported $198.63 million in quarterly revenue, up 65.7% year over year, and beat EPS expectations.

Deutsche Bank AG bought a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 854,973 shares of the biotechnology company's stock, valued at approximately $3,557,000. Deutsche Bank AG owned approximately 0.19% of Iovance Biotherapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in IOVA. State Street Corp raised its stake in shares of Iovance Biotherapeutics by 51.5% during the fourth quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company's stock valued at $55,041,000 after purchasing an additional 6,851,486 shares in the last quarter. Palo Alto Investors LP grew its position in Iovance Biotherapeutics by 122.1% in the 3rd quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company's stock valued at $16,531,000 after buying an additional 4,188,803 shares in the last quarter. HRT Financial LP increased its stake in Iovance Biotherapeutics by 1,078.3% during the 4th quarter. HRT Financial LP now owns 4,356,010 shares of the biotechnology company's stock valued at $11,891,000 after buying an additional 3,986,314 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Iovance Biotherapeutics by 202.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company's stock worth $19,239,000 after buying an additional 3,869,617 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Iovance Biotherapeutics by 13.1% during the 4th quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company's stock worth $74,275,000 after buying an additional 3,148,096 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of Iovance Biotherapeutics from $4.00 to $7.00 and gave the company a "neutral" rating in a report on Thursday, August 20th. Barclays boosted their target price on Iovance Biotherapeutics from $11.00 to $13.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Robert W. Baird set a $6.00 price target on Iovance Biotherapeutics in a research note on Friday, August 7th. Mizuho lifted their price target on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an "outperform" rating in a research report on Tuesday, August 18th. Finally, TD Cowen boosted their price objective on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Monday. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $8.89.

Iovance Biotherapeutics Stock Down 4.3%

IOVA opened at $8.08 on Thursday. The firm has a market cap of $3.66 billion, a PE ratio of -11.07 and a beta of 0.71. The business has a fifty day simple moving average of $5.30 and a 200-day simple moving average of $4.25. Iovance Biotherapeutics, Inc. has a fifty-two week low of $1.76 and a fifty-two week high of $9.36.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. The business had revenue of $198.63 million during the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%.Iovance Biotherapeutics's revenue was up 65.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) earnings per share. On average, equities research analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.48 EPS for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source